Iterum Therapeutics PLC (ITRM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Iterum Therapeutics PLC (ITRM) has a cash flow conversion efficiency ratio of 1.063x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.85 Million) by net assets ($-7.38 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ITRM net asset quality index to measure how much of total assets are equity-financed.
Iterum Therapeutics PLC - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Iterum Therapeutics PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how high is Iterum Therapeutics PLC's earnings quality to evaluate the quality of earnings relative to operating cash generation.
Iterum Therapeutics PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Iterum Therapeutics PLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Magnetic North Acquisition Corp
V:MNC
|
0.115x |
|
Bitterroot Resources Ltd
V:BTT
|
-0.011x |
|
Fidelity Japanese Values PLC ORD
LSE:FJV
|
-0.002x |
|
DSJ Keep Learning Limited
NSE:KEEPLEARN
|
0.014x |
|
8I Holdings Ltd
AU:8IH
|
-0.057x |
|
Hargreaves Services Plc
LSE:HSP
|
0.133x |
|
Playfair Mining Ltd.
V:PLY
|
0.001x |
|
Lexus Granito (India) Limited
NSE:LEXUS
|
0.322x |
Annual Cash Flow Conversion Efficiency for Iterum Therapeutics PLC (2016–2024)
The table below shows the annual cash flow conversion efficiency of Iterum Therapeutics PLC from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see ITRM stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-4.08 Million | $-26.77 Million | 6.560x | +6.79% |
| 2023-12-31 | $-6.40 Million | $-39.33 Million | 6.142x | +1030.99% |
| 2022-12-31 | $28.00 Million | $-18.47 Million | -0.660x | -109.21% |
| 2021-12-31 | $50.23 Million | $-15.84 Million | -0.315x | -129.24% |
| 2020-12-31 | $-50.56 Million | $-54.53 Million | 1.079x | -65.46% |
| 2019-12-31 | $-26.24 Million | $-81.92 Million | 3.122x | +394.67% |
| 2018-12-31 | $71.62 Million | $-75.89 Million | -1.060x | -36.74% |
| 2017-12-31 | $39.49 Million | $-30.60 Million | -0.775x | -55.47% |
| 2016-12-31 | $22.67 Million | $-11.30 Million | -0.498x | -- |
About Iterum Therapeutics PLC
Iterum Therapeutics plc, a pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States. The company offers ORLYNVAH, an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis microorganisms in adult women with lim… Read more